The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. 2000

Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
Department of Urology, Okayama University Medical School, Okayama, Japan.

OBJECTIVE To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. METHODS The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. RESULTS The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. CONCLUSIONS The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000283 Administration, Intravesical The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. Bladder Drug Administration,Drug Administration, Bladder,Instillation, Bladder,Intravesical Drug Administration,Administration, Intravesical Drug,Injections, Intravesical,Intravesical Administration,Intravesical Injection,Intravesical Instillation,Administration, Bladder Drug,Administrations, Bladder Drug,Administrations, Intravesical,Administrations, Intravesical Drug,Bladder Drug Administrations,Bladder Instillation,Bladder Instillations,Drug Administration, Intravesical,Drug Administrations, Bladder,Drug Administrations, Intravesical,Injection, Intravesical,Instillation, Intravesical,Instillations, Bladder,Instillations, Intravesical,Intravesical Administrations,Intravesical Drug Administrations,Intravesical Injections,Intravesical Instillations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
January 1998, Urologia internationalis,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
October 1990, Hinyokika kiyo. Acta urologica Japonica,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
December 1997, Hinyokika kiyo. Acta urologica Japonica,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
December 1994, International journal of urology : official journal of the Japanese Urological Association,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
May 2000, Hinyokika kiyo. Acta urologica Japonica,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
August 2000, Urology,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
January 1987, European urology,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
August 1998, Hinyokika kiyo. Acta urologica Japonica,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
September 1989, Hinyokika kiyo. Acta urologica Japonica,
Y Yamamoto, and Y Nasu, and T Saika, and T Akaeda, and T Tsushima, and H Kumon
January 1992, International urology and nephrology,
Copied contents to your clipboard!